GET DAILY SIGNALSArdelyx (ARDX) Delivers Q3 Revenue Growth of 19% and Narrows Loss Ahead of 2027 Profitability Target
Key Takeaways
- Total product revenue rose 19% year over year to $125.5 million, driven primarily by its lead product IBSRELA.
- IBSRELA revenue climbed 23% to $96.3 million, while XPHOZAH grew 7% to $29.2 million.
- The net loss narrowed to roughly $700,000, approaching breakeven, with $285.3 million in cash and short-term investments at quarter-end.
- Management reaffirmed full-year 2026 guidance for both products and for operating expenses.
- The ACCEL Phase III trial of IBSRELA in chronic idiopathic constipation (CIC) completed enrollment ahead of schedule, with results expected in the second half of 2027.
- Shares rose more than 9% in after-hours trading following the report.
Earnings Context and Why It Matters
Ardelyx's third-quarter update tests whether the company can convert strong demand for its two commercial products—IBSRELA and XPHOZAH—into durable revenue growth and, ultimately, profitability. The business has been navigating payer friction and prior authorization hurdles that slow new IBSRELA prescriptions, while absorbing higher operating costs tied to an expanded sales force and its first direct-to-consumer (DTC) advertising campaign. After lowering its full-year 2026 IBSRELA guidance earlier this year, management entered the quarter needing to demonstrate execution. These results offer a read on whether access initiatives are gaining traction and whether the company remains on track for its stated goal of profitability in 2027. I also checked this using Tickeron’s AI Screener to see how ARDX compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Ardelyx reported total product revenue of $125.5 million, up 19% from $105.5 million in the same period a year earlier. IBSRELA (tenapanor), approved for irritable bowel syndrome with constipation (IBS-C), generated $96.3 million, a 23% increase year over year. XPHOZAH (tenapanor), approved for hyperphosphatemia in adults with chronic kidney disease (CKD) on dialysis, contributed $29.2 million, up 7%.
On the bottom line, the company's net loss narrowed to approximately $700,000, compared with a loss of about $1 million a year earlier—effectively breakeven for the quarter. Research and development (R&D) expenses rose to $25.2 million from $18.1 million, reflecting investment in the ACCEL trial, while selling, general and administrative (SG&A) expenses increased to $93.9 million from $83.6 million. Ardelyx ended the quarter with $285.3 million in cash, equivalents, and short-term investments.
Management reaffirmed full-year 2026 guidance of $350 million to $370 million for IBSRELA and $110 million to $120 million for XPHOZAH, with operating expenses expected below $500 million.
Market Reaction and Investor Sentiment
Investors responded favorably to the report, with ARDX shares rising roughly 9.6% in after-hours trading to about $3.32 after closing the regular session near $3.03. The stock has been under pressure through much of the year, down approximately 48% year to date and more than half over the prior six months, leaving it toward the lower end of its 52-week range.
The positive move came despite total revenue landing slightly below some consensus estimates, which had projected around $128 million to $129 million. Instead, the market appeared to focus on the durability of IBSRELA demand, the sharply narrowed loss, a robust cash position, and management's decision to reaffirm full-year guidance. The after-hours reaction suggests investors weighed the long-term commercial trajectory and the approaching profitability milestone more heavily than the modest revenue shortfall.
Forward Outlook and Key Factors to Monitor
Following this report, the central question is whether Ardelyx can sustain IBSRELA's growth while managing access friction. The company has expanded its sales force, doubled its field reimbursement team, and launched its first DTC advertising campaign. Investors will be watching whether these initiatives translate into higher prescription fulfillment and new patient starts over the next several quarters. From what I see, this is important because it sets the stage for the 2027 profitability goal.
On the pipeline front, the ACCEL Phase III trial of IBSRELA in CIC is now fully enrolled ahead of schedule, with top-line results expected in the second half of 2027. A positive readout would represent a meaningful potential expansion of the product's addressable market.
For XPHOZAH, the evolving dialysis reimbursement environment remains a key variable. Management has indicated it will wait until it has greater clarity on that landscape before reinstating a longer-term revenue framework for the product. Finally, cost discipline will be important: while the greater than 95% gross margin supports operating leverage, rising R&D and SG&A spending means expense management will help determine how quickly the company reaches its 2027 profitability target.
Using AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when evaluating names like ARDX after earnings. It lets me quickly filter for technical patterns, fundamentals, and performance metrics across the sector, helping confirm whether the setup aligns with broader trends. The tool has become a regular part of how I cross-check ideas and identify comparable opportunities without spending hours on manual work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARDX in upward trend: price may jump up because it broke its lower Bollinger Band on October 26, 2026
ARDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 22 of 26 cases where ARDX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARDX's RSI Indicator exited the oversold zone, 18 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where ARDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +4.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARDX advanced for three days, in 224 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARDX as a result. In 58 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for ARDX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. ARDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.250) is normal, around the industry mean (3.104). P/E Ratio (-13.174) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (50.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (1.846) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases
Industry Biotechnology
Advertisement